Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...
A newly discovered RNA-based mechanism helps CRISPR systems maintain efficiency by preventing interference, offering insights ...
Recent commentary has highlighted CRISPR Therapeutics’ expanding gene-editing pipeline, including cardiovascular candidates like CTX310 and CTX320 and programs in type 1 diabetes, alongside fresh Buy ...
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Charles Gersbach and his colleagues are pursuing promising CRISPR technologies focused on controlling gene activity rather ...
We'll know more about the company's medium-term prospects by the end of the year.
CRISPR Therapeutics (CRSP) stock dropped 11% after missing Q1 estimates badly. Regeneron's free gene therapy approval adds ...
Live Science on MSN
$3 million prize goes to duo whose research led to first sickle cell CRISPR therapy
Dr. Swee Lay Thein and Dr. Stuart Orkin won the $3 million Breakthrough Prize in Life Sciences for their work toward a ...
Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of ...
Genome‑wide CRISPR screens in primary human T cells reveal human genes that promote or block HIV infection, uncovering potent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results